Nutriband

Nutriband is a transdermal-focused pharmaceutical company based in the United States.

Offering Type:
Dual Listing

Asset Type:
Common Stock (Equity)

Upstream Ticker Symbol:
NTRB

Invest in Nutriband

Important: U.S. investors may not deposit, buy, or sell securities Upstream. For more information, please visit the Upstream Support Center

Important: U.S. investors may not deposit, buy, or sell securities Upstream. For more information, please visit the Upstream Support Center

Visit the Support Center for help on Upstream.

Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The Company's lead product is its patented AVERSA Transdermal Abuse Deterrent Technology which incorporates aversive agents to prevent the Abuse, diVERsion, miSuse and Accidental exposure of drugs with abuse potential, specifically opioids. This technology can be added to virtually any patch on the market today. The majority of the revenue is currently generated from contract manufacturing and Clinical development however AVERSA Fentanyl, the Company's first product candidate, has been independently estimated by a leading healthcare consulting firm to reach peak annual sales of $85-200 M following a thorough market opportunity assessment.

  • The Company's lead product is its patented AVERSA Transdermal Abuse Deterrent Technology which incorporates aversive agents to prevent the Abuse, diVERsion, miSuse and Accidental exposure of drugs with abuse potential, specifically opioids.
  • Primarily engaged in the development of a portfolio of transdermal(delivered through the skin) pharmaceutical products.
  • Assembled with World Class Team of industry experts with one goal, to use transdermal technology to improve treatments for patients, improve patient comfort and set safety standards for notoriously dangerous medications.
  • A value-based company, rooted in science and innovation to transform new ideas and discoveries into safer products for patients.
  • Nutriband has established comprehensive manufacturing capabilities through its December 2020 acquisition of Pocono Pharmaceuticals
  • With a growing pipeline and comprehensive capabilities across the development cycle, Nutriband is in an ideal position to accelerate growth.

Regulatory Filings

Listing Particulars:


Company Presentation


Website

News

Regulatory Filings

Stay Connected

FAQ

Important: U.S. investors may not deposit, buy, or sell securities Upstream. For more information, please visit the Upstream Support Center.

Important: U.S. investors may not deposit, buy, or sell securities Upstream. For more information, please visit the Upstream Support Center.

U.S. PERSONS MAY NOT DEPOSIT, BUY, OR SELL SECURITIES ON UPSTREAM. THE OFFER SHARES ARE ONLY SUITABLE FOR INVESTORS: (I) WHO UNDERSTAND THE POTENTIAL RISK OF CAPITAL LOSS AND THAT THERE MAY BE LIMITED LIQUIDITY IN THE UNDERLYING INVESTMENTS OF THE COMPANY; (II) FOR WHOM AN INVESTMENT IN THE OFFER SHARES IS PART OF A DIVERSIFIED INVESTMENT PROGRAM; AND (III) WHO FULLY UNDERSTAND AND ARE WILLING TO ASSUME THE RISKS INVOLVED IN SUCH AN INVESTMENT PROGRAM. IT SHOULD BE REMEMBERED THAT THE PRICE OF THE SHARES AND THE INCOME FROM THEM CAN GO DOWN AS WELL AS UP. THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION A CROWD FINANCED INITIAL PUBLIC OFFERING INVESTMENT INVOLVES RISK. YOU SHOULD NOT INVEST ANY FUNDS IN THIS OFFERING UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THESE SECURITIES HAVE NOT BEEN RECOMMENDED OR APPROVED BY UPSTREAM, MERJ, HORIZON FINTEX ADVISORS, THE REPUBLIC OF SEYCHELLES OR ANY FEDERAL SECURITIES COMMISSION OR REGULATORY AUTHORITY OF ANY OTHER JURISDICTION. THE COMPANY URGES YOU TO CAREFULLY REVIEW THE PROSPECTUS, PARTICULARLY THE SECTION TITLED "RISK FACTORS" IN THE PROSPECTUS FOR A MORE COMPLETE DISCUSSION OF THE RISK OF AN INVESTMENT IN THE COMPANY. FURTHERMORE, THESE AUTHORITIES HAVE NOT PASSED UPON THE ACCURACY OR ADEQUACY OF THE PROSPECTUS OR COMPLETENESS OF ANY OFFERING DOCUMENT OR LITERATURE. THE WEBSITE AND PROSPECTUS CONTAINS FORWARD LOOKING STATEMENTS BASED ON ASSUMPTIONS AND REFLECTS THE DIRECTORS EXPECTATIONS, ESTIMATES AND PROJECTIONS OF FUTURE EVENTS. FORWARD LOOKING STATEMENTS INCLUDE WITHOUT LIMITATION, STATEMENTS REGARDING THE PERFORMANCE, PROSPECTS, OPPORTUNITIES, PRIORITIES, TARGETS, GOALS, OBJECTIVES, STRATEGIES, GROWTH AND OUTLOOK OF THE COMPANY. OFTEN, BUT NOT ALWAYS, FORWARD LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF WORDS SUCH AS "EXPECTS", "ANTICIPATES", "PLANS", "BELIEVES", "ESTIMATES", "SEEKS", "INTENDS", "TARGETS", "PROJECTS", "FORECASTS", OR VARIATIONS (INCLUDING NEGATIVE VARIATIONS) OF SUCH WORDS AND PHRASES, OR STATE THAT CERTAIN ACTIONS, EVENTS OR RESULTS "MAY", "COULD", "WOULD", "MIGHT" OR "WILL" BE TAKEN, OCCUR OR BE ACHIEVED. FORWARD LOOKING STATEMENTS ARE BASED UPON CERTAIN MATERIAL FACTORS AND ASSUMPTIONS THAT WERE APPLIED IN DRAWING A CONCLUSION OR MAKING A FORECAST OR PROJECTION, INCLUDING ASSUMPTIONS AND ANALYSES MADE BY THE DIRECTORS IN THE LIGHT OF THEIR EXPERIENCE AND PERCEPTION OF HISTORICAL TRENDS, CURRENT CONDITIONS AND EXPECTED FUTURE DEVELOPMENTS, AS WELL AS OTHER FACTORS THAT ARE BELIEVED TO BE APPROPRIATE IN THE CIRCUMSTANCES. ALSO, FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT ARE BEYOND THE DIRECTORS CONTROL AND WHICH MAY CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENT TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH FORWARD LOOKING STATEMENTS. SUCH MATERIAL FACTORS AND ASSUMPTIONS AND RISKS AND UNCERTAINTIES INCLUDE, AMONG OTHERS, THOSE WHICH ARE INCORPORATED INTO THE PROSPECTUS AND QUALIFY ANY AND ALL FORWARD-LOOKING STATEMENTS MADE IN THE PROSPECTUS.